IN

Incanthera plc

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Incanthera plc is a therapeutics company specializing in the discovery and development of innovative technologies for the dermatology and oncology sectors. The company leverages sophisticated formulation and targeted delivery platforms to create transformative treatment solutions. Its primary commercial focus is on a dermatological skincare range, branded SKIN + CELL, designed to address previously unmet needs in the market. Originating from the Institute of Cancer Therapeutics at the University of Bradford, Incanthera is dedicated to identifying and commercializing novel therapeutics.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Incanthera plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 08:00
Earnings Release
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
English 21.4 KB
2025-08-06 08:00
Regulatory News Service
SKIN + CELL TO LAUNCH
English 24.3 KB
2025-07-09 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.6 KB
2025-06-30 08:00
Share Issue/Capital Change
Subscription, Directors' Dealing and RPT
English 51.7 KB
2025-06-18 08:00
Environmental & Social Information
New Findings on Protective Effects of Skin + CELL
English 21.1 KB
2025-03-28 08:00
Regulatory News Service
Commercial Update
English 19.0 KB
2025-03-25 16:08
Legal Proceedings Report
Resolution of Allegations of Patent Infringement
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Molecure S.A. Logo
Developing first-in-class small molecule drugs for cancer and inflammatory/fibrotic diseases.
Poland MOC
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
Nanobiotix Logo
Developing physics-based nanotherapeutics that amplify radiotherapy to treat solid tumors.
France NANO
NanoGroup S.A. Logo
Develops nanotech medical solutions for oncology, transplantology, diagnostics, and therapy.
Poland NNG
Nattaro Labs AB Logo
Develops research-based, sustainable solutions for bed bug prevention, detection, and control.
Sweden NATTA
Neovacs Logo
Develops therapeutic vaccines for autoimmune diseases & allergies, while investing in BioTech/MedTech.
France ALNEV
Newron Pharmaceuticals S.p.A. Logo
Developing novel therapies for CNS diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops MSC therapies for autoimmune diseases and offers private stem cell banking services.
Sweden NXTCL